8-K: Glass Lewis Backs Aptose-Hanmi Arrangement

Leading independent proxy advisory firm Glass Lewis recommends Aptose shareholders vote FOR the proposed Plan of Arrangement with Hanmi Pharmaceutical.

Summary

• Glass Lewis, a leading independent proxy advisory firm, has recommended that Aptose shareholders vote FOR a special resolution to approve the previously announced Plan of Arrangement with Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd.
• Under the Arrangement, Hanmi Purchasers will acquire all issued and outstanding common shares of Aptose not currently owned or controlled by them or their respective affiliates.
• Glass Lewis also recommended approval of a continuance that will result in Aptose Biosciences Inc. continuing from a corporation governed under the Canada Business Corporations Act (CBCA) to a corporation continued under the Business Corporations Act (Alberta) (ABCA).
• The proxy voting deadline for the special meeting is 11:00 a.m. (Eastern time) on Friday, March 27, 2026.
• A special meeting of shareholders (Reconvened Meeting) has been scheduled for March 31, 2026, at 11:00 a.m. (EST), to be held virtually.
• The original meeting was postponed to address comments raised by the United States Securities and Exchange Commission (SEC) on the Company's transaction statement on Schedule 13E-3, as amended.
• Aptose's Special Transaction Committee and Board of Directors unanimously recommend that shareholders vote FOR the special resolutions approving the Continuance and the Arrangement Resolution.
• Completion of the transaction is subject to satisfaction of customary closing conditions, including Court approval and approval of the TSX.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development for the proposed acquisition, as the endorsement from a key independent proxy advisor significantly increases the likelihood of shareholder approval for the Plan of Arrangement.

Positives

• Glass Lewis, a leading independent proxy advisory firm, has recommended that shareholders vote FOR the proposed Plan of Arrangement.
• Aptose's Special Transaction Committee and Board of Directors unanimously recommend voting FOR the Arrangement and the Continuance.

Negatives

• The special meeting of shareholders was postponed to address comments raised by the United States Securities and Exchange Commission (SEC) on the Company's transaction statement on Schedule 13E-3, as amended.

Risks

• The possibility that the transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy required regulatory, shareholder, and Court approvals or other conditions.
• The risk that competing offers or acquisition proposals will be made.
• The negative impact that the failure to complete the transaction for any reason could have on the price of Aptose's common shares or on the business of Aptose.
• Hanmi Purchasers' failure to pay the cash consideration at completion of the transaction.
• The business of Aptose may experience significant disruptions, including loss of employees, due to transaction-related uncertainty, industry conditions, or other factors.
• Risks relating to employee retention.
• The risk of regulatory changes that may materially impact the business or the operations of Aptose.
• Risks related to the diversion of management's attention from Aptose's ongoing business operations while the transaction is pending.

Future Outlook

The completion of the Plan of Arrangement and Continuance is subject to satisfaction of customary closing conditions, including Court approval and TSX approval. The company anticipates shareholder approval given the unanimous board recommendation and the endorsement from Glass Lewis.

Management Comments

• Aptose's Special Transaction Committee and Board of Directors unanimously recommend that the Shareholders vote FOR the special resolutions approving the Continuance and the Arrangement Resolution at the Reconvened Meeting.

Industry Context

StockSavvy.ai notes that consolidation in the biotechnology sector, particularly for clinical-stage companies like Aptose focused on oncology, is a recurring trend. Acquisitions by larger pharmaceutical companies like Hanmi often aim to integrate promising pipelines, such as Aptose's TUS compound for AML, into broader development programs, providing a potential exit for shareholders and resources for further development.

Corporate Governance

Legal Proceedings

• The special meeting was postponed to address comments raised by the United States Securities and Exchange Commission (SEC) on the Company's transaction statement on Schedule 13E-3, as amended.

Related Party Transactions

• The Plan of Arrangement involves Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd. acquiring all outstanding common shares of Aptose not currently owned or controlled by them or their respective affiliates, indicating a transaction with a significant existing shareholder.

Stakeholder Impact

• Shareholders: Will receive cash consideration for their shares upon completion of the Arrangement, assuming approval.
• Employees: The business may experience significant disruptions, including loss of employees, due to transaction-related uncertainty.
• Management: Attention may be diverted from ongoing business operations while the transaction is pending.

Next Steps

• Shareholders are encouraged to submit their proxies ahead of the proxy voting deadline of March 27, 2026.
• The Reconvened Special Meeting of Shareholders will be held on March 31, 2026, to vote on the Arrangement and Continuance.
• Completion of the transaction is subject to satisfaction of customary closing conditions, including Court approval and TSX approval.

Key Dates

Recommendation

The strong endorsement from Glass Lewis, coupled with the unanimous recommendation from Aptose's Board, significantly de-risks the shareholder approval process for the acquisition by Hanmi Pharmaceutical. This positive development makes the completion of the transaction highly probable, offering a clear exit strategy for shareholders at the agreed-upon acquisition price.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Plan of Arrangement, Acquisition, Merger, Biotechnology, Oncology, AML, Glass Lewis, Proxy Advisory, Shareholder Vote, SEC Filing, Corporate Governance, TSX, OTC